The development of palbociclib for the treatment of hormone-receptor-positive advanced BC was based on the findings of preclinical studies that identified a dependence of hormone receptor-positive BC on CDK signaling and a synergistic effect from targeting the ER, cyclin-D–CDK4/6–Rb pathway [63]. This evidence concerns the gene NR4A1 and breast cancer.